Options for treating postherpetic neuralgia in the medically complicated patient

Therapeutics and Clinical Risk Management

Volumn 9, Issue 1, 2013, Pages 329-340

  Bruckenthal, Patricia ^a   Barkin, Robert L ^b,c  

^a Stony Brook School of Dental Medicine   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c Northshore University Health System Pain Centers   (United States)

Author keywords

Calcium channel 2 delta; ligand; Comorbidities; Lidocaine patch; Polypharmacy; Postherpetic neuralgia; TCA

Indexed keywords

AMITRIPTYLINE; BENZYDAMINE; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; DESIPRAMINE; DEXTROMETHORPHAN; DULOXETINE; FENTANYL; FLUPHENAZINE; GABAPENTIN; HYDROCODONE; HYDROMORPHONE; LIDOCAINE; LORAZEPAM; MEMANTINE; METHADONE; MEXILETINE; MORPHINE; NORTRIPTYLINE; OPIATE ANTAGONIST; OXYCODONE; OXYMORPHONE; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TAPENTADOL; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ADVERSE OUTCOME; ANALGESIA; ANOREXIA; APPLICATION SITE PAIN; APPLICATION SITE REACTION; ASTHENIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COMORBIDITY; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GAIT DISORDER; HUMAN; INFECTION; KIDNEY DISEASE; LIVER DYSFUNCTION; MCGILL PAIN QUESTIONNAIRE; NAUSEA; NUMERICAL RATING SCALE; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PERIPHERAL EDEMA; POLYPHARMACY; POSTHERPETIC NEURALGIA; RATING SCALE; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; URINE RETENTION; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

EID: 84883544645     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S47138     Document Type: Review

References (129)

1. Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract. 2002;19(5):471-475.
2. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341-1349.
3. Roger VL, Go AS, Lloyd-Jones DM, etal. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125(1):188-197.
4. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33(4): 278-285.
5. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol. 1976;31(2):155-163.
6. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology. 1989;9(2):297-301.
7. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24): 2867-2878.
8. Preskorn SH, Silkey B, Shah R, etal. Complexity of medication use in the Veterans Affairs healthcare system: Part I: Outpatient use in relation to age and number of prescribers. J Psychiatr Pract. 2005;11(1): 5-15.
9. Tulner LR, Frankfort SV, Gijsen GJ, van Campen JP, Koks CH, Beijnen JH. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging. 2008;25(4):343-355.
10. Dworkin RH, O'Connor AB, Audette J, etal. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(Suppl 3):S3-S14.
11. Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med. 2011;123(5):134-142.
12. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63(6):959-965.
13. Attal N, Cruccu G, Baron R, etal. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9): 1113-e88.
14. Moulin DE, Clark AJ, Gilron I, etal; Canadian Pain Society. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12(1):13-21.
15. Dworkin RH, O'Connor AB, Backonja M, etal. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237-251.
16. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118(3):289-305.
17. Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005;2(7):e164.
18. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatr. 2010;81(12):1372-1373.
19. Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005;96(6):399-409.
20. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000;108(1):2-8.
21. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther. 2004;75(3):234-241.
22. Tata LJ, West J, Smith C, etal. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart. 2005;91(4): 465-471.
23. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009:CD007076.
24. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011:CD007938.
25. Parsons B, Tive L, Huang S. Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. Am J Geriatr Pharmacother. 2004;2(3):157-162.
26. Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract. 2010;11:85.
27. Binder A, Bruxelle J, Rogers P, Hans G, Bösl I, Baron R. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig. 2009;29(6): 393-408.
28. Hans G, Sabatowski R, Binder A, Boesl I, Rogers P, Baron R. Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. Curr Med Res Opin. 2009;25(5):1295-1305.
29. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009;25(7):1663-1676.
30. Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin. 2010;26(7): 1607-1619.
31. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology. 1998;50(6): 1837-1841.
32. Raja SN, Haythornthwaite JA, Pappagallo M, etal. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002;59(7):1015-1021.
33. Bhamb B, Brown D, Hariharan J, Anderson J, Balousek S, Fleming MF. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin. 2006;22(9): 1859-1865.
34. Spitz A, Moore AA, Papaleontiou M, Granieri E, Turner BJ, Reid MC. Primary care providers' perspective on prescribing opioids to older adults with chronic non-cancer pain: a qualitative study. BMC Geriatr. 2011;11:35.
35. Upshur CC, Luckmann RS, Savageau JA. Primary care provider concerns about management of chronic pain in community clinic populations. J Gen Intern Med. 2006;21(6):652-655.
36. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain. 2003;104(1-2):323-331.
37. NUCYNTA® ER (tapentadol) [prescribing information]. Titusville. NJ: Janssen Pharmaceuticals, Inc; 2011.
38. Afilalo M, Etropolski MS, Kuperwasser B, etal. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo-and active-controlled phase III study. Clin Drug Investig. 2010;30(8):489-505.
39. Lange B, Kuperwasser B, Okamoto A, etal. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010;27(6):381-399.
40. Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain. 1999;81(1-2):135-145.
41. Derry S, Lloyd R, Moore RA, McQuay HJ. Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2009:CD007393.
42. Backonja M, Wallace MS, Blonsky ER, etal; NGX-4010 C116 Study Group. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7(12):1106-1112.
43. Backonja MM, Malan TP, Vanhove GF, Tobias JK; C102/106 Study Group. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med. 2010;11(4):600-608.
44. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004;328(7446):991.
45. Qutenza® (capsaicin 8% patch) [prescribing information]. San Mateo, CA: NeurogesX, Inc; 2009.
46. Schmader KE, Baron R, Haanpää ML, etal. Treatment considerations for elderly and frail patients with neuropathic pain. Mayo Clin Proc. 2010;85(Suppl 3):S26-S32.
47. Parsells Kelly J, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Prevalence and characteristics of opioid use in the US adult population. Pain. 2008;138(3):507-513.
48. Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther. 2007;32(2):169-175.
49. Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine [webpage on the Internet]. Available from: http://medicine.iupui.edu/flockhart/table.htm. Accessed June 20, 2012.
50. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P4503A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687-710.
51. Bertilsson L, Lou YQ, Du YL, etal. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther. 1992;51(4):388-397.
52. Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980;17(2):102-105.
53. Bathum L, Johansson I, Ingelman-Sundberg M, Hørder M, Brøsen K. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics. 1998;8(2):119-123.
54. Løvlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996;392(1): 30-34.
55. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther. 1996;278(1):441-446.
56. Bathum L, Skjelbo E, Mutabingwa TK, Madsen H, Hørder M, Brøsen K. Phenotypes and genotypes for CYP2D6 and CYP2C19in a black Tanzanian population. Br J Clin Pharmacol. 1999;48(3):395-401.
57. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol. 1996;42(6):713-719.
58. Sohn DR, Shin SG, Park CW, Kusaka M, Chiba K, Ishizaki T. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol. 1991;32(4):504-507.
59. Lyrica® (pregabalin) [prescribing information]. New York: Pfizer Inc; 2011.
60. Neurontin® (gabapentin) [prescribing information]. New York: Pfizer Inc; 2011.
61. Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997;25(1):1-4.
62. Dilaudid® (Hydromorphone HCl) [prescribing information]. Stamford, CT: Purdue Pharma LP; 2009.
63. OPANA® ER (oxymorphone hydrochloride) [prescribing information]. Chadds Ford, PA: Endo Pharmaceuticals; 2012.
64. Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients. Drugs Aging. 2010;27(5):417-433.
65. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7): 613-624.
66. Campbell BJ, Rowbotham M, Davies PS, Jacob P, Benowitz NL. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci. 2002;91(5):1343-1350.
67. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol. 2003;43(2):111-117.
68. Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother. 2002;36(2):236-240.
69. Lidoderm® (lidocaine patch 5%) [prescribing information]. Chadds Ford, PA: Endo Pharmaceuticals Inc; 2010.
70. Babbar S, Marier JF, Mouksassi MS, etal. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther Drug Monit. 2009;31(4):502-510.
71. Amitriptyline hydrochloride [prescribing information]. Princeton, NJ: Sandoz Inc; 2011.
72. Nortriptyline hydrochloride [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; 2007.
73. Norpramin® (desipramine hydrdochloride) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; 2011.
74. Mahlberg R, Kunz D, Sasse J, Kirchheiner J. Serotonin syndrome with tramadol and citalopram. Am J Psychiatry. 2004;161(6):1129.
75. Takeshita J, Litzinger MH. Serotonin syndrome associated with tramadol. Prim Care Companion J Clin Psychiatry. 2009;11(5):273.
76. Vizcaychipi MP, Walker S, Palazzo M. Serotonin syndrome triggered by tramadol. Br J Anaesth. 2007;99(6):919.
77. Ultram ER® (tramadol hydrochloride) [prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2009.
78. Center for Drug Evaluation and Research. Guidance for industry: pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling. Springville, MD: Food and Drug Administration; Mar 2010.
79. Schiller JS, Lucas JW, Ward BW, Peregoy JA. Summary health statistics for US adults: National Health Interview Survey, 2010. National Center for Health Statistics. Vital Health Statistics. Vital Health Statistics. 2012:10(252).
80. Clomipramine hydrochloride [prescribing information]. Princeton, NJ: Sandoz Inc; 2011.
81. MS Contin® (morphine extended release) [prescribing information]. Hazelwood, MO: Mallinckrodt; 2010.
82. OxyContin® (oxycodone HCl controlled-release tablets) [prescribing information]. Stamford, CT: Purdue Pharma LLP; 2012.
83. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497-504.
84. Duragesic® (fentanyl transdermal system) [prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2009.
85. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331-1346.
86. Milne RW, Nation RL, Somogyi AA, Bochner F, Griggs WM. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. Br J Clin Pharmacol. 1992;34(1):53-59.
87. Wolff J, Bigler D, Christensen CB, Rasmussen SN, Andersen HB, Tønnesen KH. Influence of renal function on the elimination of morphine and morphine glucuronides. Eur J Clin Pharmacol. 1988;34(4): 353-357.
88. Babul N, Darke AC, Hagen N. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage. 1995;10(3):184-186.
89. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol. 2000;27(7):524-528.
90. Angst MS, Bührer M, Lötsch J. Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action. Anesthesiology. 2000;92(5):1473-1476.
91. Dubs A, Wiedemeier P, Caduff B. Morphine poisoning in chronic kidney failure. Morphine-6-glucuronide as a pharmacologically active morphine metabolite. Dtsch Med Wochenschr. 1999;124(30):896-898. German.
92. Hagen NA, Foley KM, Cerbone DJ, Portenoy RK, Inturrisi CE. Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage. 1991;6(3):125-128.
93. Guay DR, Awni WM, Findlay JW, etal. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther. 1988;43(1):63-71.
94. Talbott GA, Lynn AM, Levy FH, Zelikovic I. Respiratory arrest precipitated by codeine in a child with chronic renal failure. Clin Pediatr (Phila). 1997;36(3):171-173.
95. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 2006;74(5):756-762.
96. Crotty B, Watson KJ, Desmond PV, etal. Hepatic extraction of morphine is impaired in cirrhosis. Eur J Clin Pharmacol. 1989;36(5): 501-506.
97. Durnin C, Hind ID, Ghani SP, Yates DB, Molz KH. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment. Proc West Pharmacol Soc. 2001;44:83-84.
98. Haberer JP, Schoeffler P, Couderc E, Duvaldestin P. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth. 1982;54(12):1267-1270.
99. Simpson DM, Gazda S, Brown S, etal; NGX-4010 C118 Study Group. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage. 2010;39(6):1053-1064.
100. Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther. 2003;74(2):102-112.
101. Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart. 2007;93(9):1051-1055.
102. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007;167(22):2469-2475.
103. Peacock WF, Hollander JE, Diercks DB, Lopatin M, Fonarow G, Emerman CL. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J. 2008;25(4):205-209.
104. Gruber EM, Tschernko EM. Anaesthesia and postoperative analgesia in older patients with chronic obstructive pulmonary disease: special considerations. Drugs Aging. 2003;20(5):347-360.
105. Walker JM, Farney RJ, Rhondeau SM, etal. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med. 2007;3(5):455-461.
106. Webster LR, Choi Y, Desai H, Webster L, Grant BJ. Sleep-disordered breathing and chronic opioid therapy. Pain Med. 2008;9(4): 425-432.
107. Tarkkila P, Tuominen M, Lindgren L. Comparison of respiratory effects of tramadol and oxycodone. J Clin Anesth. 1997;9(7):582-585.
108. Codeine sulfate tablets [prescribing information]. Columbus, OH: Roxane Laboratories, Inc; 2010.
109. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634-1642.
110. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008;371(9624):1612-1623.
111. Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology. 1998;51(4):1166-1171.
112. Bailey B, Buckley NA, Amre DK. A meta-analysis of prognostic indicators to predict seizures, arrhythmias or death after tricyclic antidepressant overdose. J Toxicol Clin Toxicol. 2004;42(6):877-888.
113. Fong HK, Sands LP, Leung JM. The role of postoperative analgesia in delirium and cognitive decline in elderly patients: a systematic review. Anesth Analg. 2006;102(4):1255-1266.
114. Lawlor PG. The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal. Cancer. 2002;94(6): 1836-1853.
115. Morita T, Takigawa C, Onishi H, etal; Japan Pain, Rehabilitation, Palliative Medicine, and Psycho-Oncology (PRPP) Study Group. Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial. J Pain Symptom Manage. 2005;30(1):96-103.
116. Morita T, Tei Y, Tsunoda J, Inoue S, Chihara S. Increased plasma morphine metabolites in terminally ill cancer patients with delirium: an intra-individual comparison. J Pain Symptom Manage. 2002;23(2): 107-113.
117. Leung JM, Sands LP, Paul S, Joseph T, Kinjo S, Tsai T. Does postoperative delirium limit the use of patient-controlled analgesia in older surgical patients? Anesthesiology. 2009;111(3):625-631.
118. Nortriptyline hydrochloride solution [prescribing information]. Jacksonville, FL: Ranbaxy Pharmaceuticals Inc; 2008.
119. Gabapentin oral solution [prescribing information]. Gainesville, FL: Kiel Laboratories, Inc; 2012.
120. Lyrica oral solution (pregabalin hydrochloride oral solution) [prescribing information]. Kalamazoo, MI: Pfizer Inc; 2012.
121. Stone M, Laughren T, Jones ML, etal. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880.
122. Patorno E, Bohn RL, Wahl PM, etal. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA. 2010;303(14):1401-1409.
123. Gibbons RD, Hur K, Brown CH, Mann JJ. Gabapentin and suicide attempts. Pharmacoepidemiol Drug Saf. 2010;19(12):1241-1247.
124. Sullivan MD, Edlund MJ, Steffick D, Unützer J. Regular use of prescribed opioids: association with common psychiatric disorders. Pain. 2005;119(1-3):95-103.
125. Barkin RL, Barkin SJ. Reexamining the Elderly Patient's Presentation With Depression. Prim Care Companion J Clin Psychiatry. 2008;10(5):415-416.
126. Substance Abuse and Mental Health Services Administration. Results From The 2011 National Survey On Drug Use And Health: Summary Of National Findings. NSDUH Series H-44, HHS Publication No (SMA) 12-4713. Rockville, MD: Food and Drug Administration; 2012.
127. Manchikanti L, Cash KA, Damron KS, Manchukonda R, Pampati V, McManus CD. Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables. Pain Physician. 2006;9(3):215-225.
128. Kirsh KL, Smith HS. Special issues and concerns in the evaluation of older adults who have pain. Clin Geriatr Med. 2008;24(2): 263-274, vi.
129. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6(2):107-112.